- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Negative priming.
Displaying page 1 of 2.
EudraCT Number: 2005-005849-19 | Sponsor Protocol Number: RHM MED 0673 | Start Date*: 2006-07-06 |
Sponsor Name:Southampton University Hospitals NHS Trust | ||
Full Title: Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients | ||
Medical condition: pre-cirrhotic chronic hepatitis B virus (HBV) infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005133-30 | Sponsor Protocol Number: 810802 | Start Date*: 2009-01-22 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers... | |||||||||||||
Medical condition: H5N1 vaccination with a single Prime-Boost Vaccination schedule in healthy subjects aged 18 to 59 years. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005477-22 | Sponsor Protocol Number: 107495 | Start Date*: 2007-01-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H... | ||
Medical condition: Immunization against influenza disease during pandemic in subjects aged 18 to 60 years. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000097-23 | Sponsor Protocol Number: SAM109352 | Start Date*: 2007-09-04 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001441-14 | Sponsor Protocol Number: IFOM-CPT002/2018/PO001 | Start Date*: 2018-10-29 | |||||||||||
Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano | |||||||||||||
Full Title: PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS | |||||||||||||
Medical condition: RAS mutated metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000044-22 | Sponsor Protocol Number: C1071005 | Start Date*: 2021-09-14 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALI... | |||||||||||||
Medical condition: MULTIPLE MYELOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) PL (Trial now transitioned) ES (Restarted) IT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000261-38 | Sponsor Protocol Number: 108988 | Start Date*: 2008-01-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Bio... | ||
Medical condition: Hepatitis B vaccine challenge dose given to subjects, 17 to 21 years of age, to evaluate immune memory to Hepatitis B antigen, approximately 6 years after priming with Hepatitis B vaccine. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018332-41 | Sponsor Protocol Number: RibaC | Start Date*: 2010-05-10 | |||||||||||
Sponsor Name:Dept. of Infectious diseases / virology University of Gothenburg | |||||||||||||
Full Title: A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon... | |||||||||||||
Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001584-20 | Sponsor Protocol Number: 207543 | Start Date*: 2017-10-02 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-se... | ||
Medical condition: Healthy volunteers (active immunization for the prevention of disease caused by influenza virus) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004504-35 | Sponsor Protocol Number: RF-2010-2311148 | Start Date*: 2013-02-26 | |||||||||||
Sponsor Name:IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI | |||||||||||||
Full Title: The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-000944-46 | Sponsor Protocol Number: 217218 | Start Date*: 2024-05-31 |
Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA | ||
Full Title: A Phase IIa observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine agains... | ||
Medical condition: Prevention of invasive nontyphoidal Salmonella disease | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2006-003424-12 | Sponsor Protocol Number: CD66-02 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: A randomised phase II clinical trial using targeted radiotherapy delivered by an Yttrium-90 radiolabelled Anti-CD66 monoclonal antibody with high dose melphalan compared to melphalan alone, prior t... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001669-11 | Sponsor Protocol Number: IFOM-CPT008/2022/PO007 | Start Date*: 2022-09-22 | |||||||||||||||||||||
Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare - Milano | |||||||||||||||||||||||
Full Title: Restoring sensitivity to immunotherapy in advanced triple negative breast cancer exploiting Ceralasertib priming followed by combined Durvalumab/Nab-paclitaxel: The ATRiBRAVE Trial. | |||||||||||||||||||||||
Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000142-34 | Sponsor Protocol Number: ITCC-092/IST11028 | Start Date*: 2020-09-15 | ||||||||||||||||
Sponsor Name:Princess Máxima Center for pediatric oncology | ||||||||||||||||||
Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092 | ||||||||||||||||||
Medical condition: Relapsed or refractory pediatric acute myeloid leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005143-13 | Sponsor Protocol Number: ONCOS-C719 | Start Date*: 2016-05-06 | |||||||||||
Sponsor Name:Targovax Oy | |||||||||||||
Full Title: A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectab... | |||||||||||||
Medical condition: Patients with unresectable malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000115-28 | Sponsor Protocol Number: 109817 | Start Date*: 2007-07-16 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in a... | ||
Medical condition: Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Preven... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001448-31 | Sponsor Protocol Number: H01_04E1TP | Start Date*: 2011-09-12 | |||||||||||
Sponsor Name:Novartis Vaccines Institute for Global Health (NVGH) | |||||||||||||
Full Title: A Phase 2, open-label, single-center, extension study to evaluate the booster response induced by Vi-CRM197 after priming with either Vi-CRM197 or Typherix administered in adult subjects in H01_04T... | |||||||||||||
Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004353-24 | Sponsor Protocol Number: LAMVYX | Start Date*: 2019-11-04 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute... | |||||||||||||
Medical condition: Newly diagnosed secondary or high risk AML | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004287-26 | Sponsor Protocol Number: 5F9009 | Start Date*: 2021-05-19 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplas... | |||||||||||||
Medical condition: Intermediate/high/very high risk myelodysplastic syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Prematurely Ended) BE (Completed) IE (Prematurely Ended) NL (Completed) AT (Prematurely Ended) DK (Prematurely Ended) PT (Prematurely Ended) NO (Prematurely Ended) FI (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002718-38 | Sponsor Protocol Number: 111670 | Start Date*: 2015-06-10 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologic... | ||||||||||||||||||
Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
